Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

PTGX - Protagonist Therapeutics Inc Stock Price, Fair Value and News

$64.53+2.33 (+3.75%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PTGX Price Action

Last 7 days

5.7%

Last 30 days

10.7%

Last 90 days

16.7%

Trailing 12 Months

35.5%

PTGX RSI Chart

2025FebMarAprMayJunJulAugSep0102030405060708090

PTGX Valuation

Market Cap

4.0B

Price/Earnings (Trailing)

77.15

Price/Sales (Trailing)

19.19

EV/EBITDA

70.35

Price/Free Cashflow

108.21

PTGX Price/Sales (Trailing)

202320242025102030405060

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PTGX Fundamentals

PTGX Revenue

Revenue (TTM)

209.2M

Rev. Growth (Yr)

33.09%

Rev. Growth (Qtr)

-80.42%

20182020202220240100M200M300M400M

PTGX Earnings

Earnings (TTM)

52.0M

Earnings Growth (Yr)

-13.57%

Earnings Growth (Qtr)

-198.34%

20162018202020222024-100M0100M200M300M

PTGX Profitability

EBT Margin

25.71%

Return on Equity

7.79%

Return on Assets

7.25%

Free Cashflow Yield

0.92%

PTGX Investor Care

Shares Dilution (1Y)

5.61%

Diluted EPS (TTM)

0.73

PTGX Alerts

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
20182019202020212022202320242025050M100M150M200M250M300M350M400M450M
Net sales
YearQ1Q2Q3Q4
2025207.8M209.2M00
2024153.6M247.2M340.8M434.4M
202300060.0M
202246.9M45.5M35.2M26.6M
202131.2M27.2M24.4M27.4M
202020.0M22.8M25.7M28.6M
201921.7M014.2M17.1M
201831.3M42.5M39.9M30.9M
201700020.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
 CEO
 WEBSITEprotagonist-inc.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES106

Protagonist Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Protagonist Therapeutics Inc? What does PTGX stand for in stocks?

PTGX is the stock ticker symbol of Protagonist Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Protagonist Therapeutics Inc (PTGX)?

As of Fri Sep 19 2025, market cap of Protagonist Therapeutics Inc is 3.87 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTGX stock?

You can check PTGX's fair value in chart for subscribers.

Is Protagonist Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PTGX is over valued or under valued. Whether Protagonist Therapeutics Inc is cheap or expensive depends on the assumptions which impact Protagonist Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTGX.

What is Protagonist Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Sep 19 2025, PTGX's PE ratio (Price to Earnings) is 74.36 and Price to Sales (PS) ratio is 18.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTGX PE ratio will change depending on the future growth rate expectations of investors.